Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
For patients with obesity or type 2 diabetes, the benefits of semaglutide (weight loss, blood sugar control, heart protection) often outweigh the risks
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
We are thrilled that this reclassification will allow us to once again offer a broader range of peptide therapies to support your health and wellness goals
It has a long-standing place in veterinary conversations about certain forms of cardiomyopathy and nutritional heart support
